Clinical trials: Early Onset Alzheimer Disease, active
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Alzheimer Dementia, Presenile Alzheimer Dementia
Individualized Brain Stimulation to Improve Mobility in Alzheimer's Disease
The objective of this study is to conduct a pilot, randomized sham-controlled trials to determine the feasibility and effects of a 10-session personalized tDCS intervention targeting the left dorsolateral prefrontal cortex on…
- Conditions
- Alzheimer Dementia, Presenile Alzheimer Dementia, Aging
- Trial name
- ISTIM-AD (NCT04289402)
- Testing
- Personalized tDCS
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hebrew SeniorLife
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer Disease, Early Onset
Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE
The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD.
- Trial name
- NCT07107074
- Testing
- AD04
- Where
- 3 sites in Austria, Poland
- Volunteers
- 122 people
- Sponsor
- ADvantage Therapeutics
Alzheimer's Disease, Dementia
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of…
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Trial name
- DIAN-TU (NCT06384573)
- Testing
- lecanemab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease, Early Onset
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
- Trial name
- NCT06750432
- Testing
- PMN310
- Where
- 22 sites in United States
- Volunteers
- 144 people
- Sponsor
- ProMis Neurosciences, Inc
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Down Syndrome, Cognitive Decline
GnRH Therapy on Cognition in Down Syndrome
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old.
- Conditions
- Down Syndrome, Cognitive Decline, Alzheimer Disease, Early Onset, Olfaction Disorders
- Trial name
- NCT04390646
- Testing
- GnRH, gonadorelin acetate, 0.9% NaCl
- Where
- Switzerland
- Volunteers
- 56 people
- Sponsor
- Nelly Pitteloud
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Early Onset Alzheimer Disease
48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
- Trial name
- NCT04002583
- Testing
- Computer assisted ambulatory electroencephalogram
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Delirium, Cognitive Impairment
Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study
Cognitive skills are essential to live independently, manage finances, maintain employment, and function in society. Loss of these cognitive skills puts a tremendous burden on society as seen with dementias, Alzheimer's disease…
- Conditions
- Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma
- Trial name
- INSIGHT-ICU (NCT03098459)
- Testing
- Non-interventional observational prospective cohort study
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Vanderbilt University Medical Center
Alzheimer Disease, Early Onset
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants…
- Trial name
- NCT07328451
- Testing
- DNL628
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Denali Therapeutics Inc.
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating…
- Conditions
- Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
- Trial name
- NCT04122001
- Testing
- Active, in-person HD-tDCS or active remote tDCS, Word List Learning Intervention (WordLLI)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer Disease, Alzheimer Disease, Early Onset
Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease
New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies.
- Trial name
- TMSLA (NCT07036328)
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Netherlands
- Volunteers
- 55 people
- Sponsor
- Willem de Haan
Alzheimer Disease, Early Onset
Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study
The purpose of this study is to generate preliminary data on the benefit of computerized cognitive training and Tai Chi- Qi Gong training in participants with Early-Onset Alzheimer's Disease.
- Trial name
- LITES (NCT05573490)
- Testing
- Cognitive Training, Tai Chi- Qi Gong, Brain Games
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Indiana University
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital